JP2024515344A5 - - Google Patents
Info
- Publication number
- JP2024515344A5 JP2024515344A5 JP2023564255A JP2023564255A JP2024515344A5 JP 2024515344 A5 JP2024515344 A5 JP 2024515344A5 JP 2023564255 A JP2023564255 A JP 2023564255A JP 2023564255 A JP2023564255 A JP 2023564255A JP 2024515344 A5 JP2024515344 A5 JP 2024515344A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025066627A JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177254P | 2021-04-20 | 2021-04-20 | |
| US63/177,254 | 2021-04-20 | ||
| PCT/US2022/025648 WO2022226127A1 (en) | 2021-04-20 | 2022-04-20 | Compositions and methods for inhibiting complement component 3 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066627A Division JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515344A JP2024515344A (ja) | 2024-04-09 |
| JPWO2022226127A5 JPWO2022226127A5 (https=) | 2025-04-23 |
| JP2024515344A5 true JP2024515344A5 (https=) | 2025-04-23 |
Family
ID=83723122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564255A Pending JP2024515344A (ja) | 2021-04-20 | 2022-04-20 | 補体成分３の発現を阻害するための組成物及び方法 |
| JP2025066627A Pending JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066627A Pending JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250002908A1 (https=) |
| EP (1) | EP4326876A4 (https=) |
| JP (2) | JP2024515344A (https=) |
| KR (1) | KR20230173116A (https=) |
| CN (1) | CN117295819A (https=) |
| AU (1) | AU2022261922A1 (https=) |
| BR (1) | BR112023021703A2 (https=) |
| CA (1) | CA3177629A1 (https=) |
| CO (1) | CO2023014681A2 (https=) |
| IL (1) | IL307721A (https=) |
| MX (1) | MX2023012385A (https=) |
| WO (1) | WO2022226127A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI868755B (zh) | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| WO2024169907A1 (zh) * | 2023-02-17 | 2024-08-22 | 苏州时安生物技术有限公司 | 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途 |
| CN121488036A (zh) * | 2023-07-21 | 2026-02-06 | 上海舶望制药有限公司 | 用于抑制补体成分3(c3)表达的组合物和方法 |
| WO2025168134A1 (zh) * | 2024-02-08 | 2025-08-14 | 北京安龙生物医药有限公司 | 靶向补体成分c3基因的寡核苷酸及其用途 |
| CN121154665B (zh) * | 2025-11-21 | 2026-02-27 | 天津医科大学第二医院 | 尿苷在防治糖尿病肾病药物开发过程中及药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305812A3 (en) * | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| WO2007064846A2 (en) * | 2005-11-30 | 2007-06-07 | Intradigm Corporation | COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO IMPROVE SOLID ORGAN AND CELL TRANSPLANTATION |
| WO2010042755A2 (en) * | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric therapeutics, compositions, and methods for using same |
| SG10201804960RA (en) * | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| RU2019113301A (ru) * | 2016-10-17 | 2020-11-17 | Апеллис Фармасьютикалс, Инк. | Комбинированная терапия для ингибирования с3 |
| AU2018360697A1 (en) * | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| CA3119234A1 (en) * | 2018-11-23 | 2020-05-28 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of c3 in a cell |
| EP4022060A1 (en) * | 2019-08-27 | 2022-07-06 | Silence Therapeutics GmbH | Nucleic acids for inhibiting expression of c3 in a cell |
| TW202134435A (zh) * | 2019-10-22 | 2021-09-16 | 美商阿尼拉製藥公司 | 補體成分ｃ３ ｉｒｎａ組成物及其使用方法 |
| CN115335524A (zh) * | 2020-02-14 | 2022-11-11 | 阿佩利斯制药有限公司 | 用于补体抑制的rna |
| MX2023008469A (es) * | 2021-01-22 | 2023-11-22 | Alnylam Pharmaceuticals Inc | Oligonucleotidos de doble hebra modificados. |
| WO2022251484A1 (en) * | 2021-05-26 | 2022-12-01 | Apellis Pharmaceuticals, Inc. | Treatment of complement-mediated disorders |
-
2022
- 2022-04-20 WO PCT/US2022/025648 patent/WO2022226127A1/en not_active Ceased
- 2022-04-20 CN CN202280034163.4A patent/CN117295819A/zh active Pending
- 2022-04-20 MX MX2023012385A patent/MX2023012385A/es unknown
- 2022-04-20 KR KR1020237036421A patent/KR20230173116A/ko active Pending
- 2022-04-20 AU AU2022261922A patent/AU2022261922A1/en active Pending
- 2022-04-20 CA CA3177629A patent/CA3177629A1/en active Pending
- 2022-04-20 IL IL307721A patent/IL307721A/en unknown
- 2022-04-20 US US18/287,260 patent/US20250002908A1/en active Pending
- 2022-04-20 JP JP2023564255A patent/JP2024515344A/ja active Pending
- 2022-04-20 BR BR112023021703A patent/BR112023021703A2/pt unknown
- 2022-04-20 EP EP22792454.5A patent/EP4326876A4/en active Pending
-
2023
- 2023-10-30 CO CONC2023/0014681A patent/CO2023014681A2/es unknown
-
2025
- 2025-04-15 JP JP2025066627A patent/JP2025100729A/ja active Pending